Chemical structure of molecule reldesemtiv

second gen. oral troponin activator

Ph. III candidate for ALS (300 mg BID)

from HTS in muscle assay and reducing BP

Journal of Medicinal Chemistry

Cytokinetics, South San Francisco, CA

The Cytokinetics second generation troponin activator, reldesemtiv, is intended to treat muscle weakness by directly activating skeletal muscle. A high concentration of free drug is expected to be needed due…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.